TenoMiR in lateral epicondylitis

Phase 1, randomised, double-blind trial in Lateral Epicondylitis (LET) comparing Treatment (TenoMiR) with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events as assessed by clinical laboratory abnormalities at 14 days, Incidence of Treatment-Emergent Adverse Events as assessed by changes in vital signs at 14 days and 3 more. Started Aug 2020; status: completed.